Tolterodine extended-release for overactive bladder

Bibliography

• Abrams P, Cardozo L, et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Irwin D, Milsom I, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Stewart W, Van Rooyen J, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20(6):327-36
   PubMed Web of Science ®Google Scholar
• Wagner T, Hu T, et al. Health-related consequences of overactive bladder. Am J Manag Care 2002;8(19 Suppl):S598-607
   PubMed Web of Science ®Google Scholar
• Coyne K, Sexton C, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101:1388-95
   PubMed Web of Science ®Google Scholar
• Brading A, Turner W. The unstable bladder: towards a common mechanism. Br J Urol 1994;73:3-8
   PubMedGoogle Scholar
• de Groat W. A neurologic basis for the overactive bladder. Urology 1997;50:36-52s
   PubMed Web of Science ®Google Scholar
• Drake M, Mills I, et al. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001;358:401-3
   PubMed Web of Science ®Google Scholar
• Mansfield K, Liu L, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR changes in ageing. Br J Pharmacol 2005;144:1089-99
   PubMed Web of Science ®Google Scholar
• Tyagi S, Tyagi P, et al. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 2006;176:1673-8
   PubMed Web of Science ®Google Scholar
• Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology 2009;83:259-69
   PubMed Web of Science ®Google Scholar
• Matsui M, Motomura D, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci USA 2000;97:9579-84
   PubMedGoogle Scholar
• Giglio D, Ryberg A, et al. Altered muscarinic receptor subtype expression and functional responses in cyclophosphamide induced cystitis in rats. Auton Neurosci 2005;122:9-20
   PubMedGoogle Scholar
• Yarker Y, Goa KF, et al. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-62
   PubMed Web of Science ®Google Scholar
• Abrams P, Freeman R, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10
   PubMedGoogle Scholar
• Van Kerrebroeck P, Kreder K, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001;57:414-21
   PubMed Web of Science ®Google Scholar
• Rovner E, Wein A. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002;41:6-14
   PubMed Web of Science ®Google Scholar
• Nilvebrandt L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000;11:13-27
   Google Scholar
• Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001;40:227-35
   PubMed Web of Science ®Google Scholar
• Brynne N, Forslund C, et al. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1998;48:564-72
   Google Scholar
• Brynne N, Stahl M, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997;35:287-95
   PubMed Web of Science ®Google Scholar
• Alvan G, Bechtel P, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7
   PubMed Web of Science ®Google Scholar
• Pahlman I, Gozzi P. Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm Drug Dispos 1999;20:91-9
   PubMed Web of Science ®Google Scholar
• Brynne N, Dalen P, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 1998;63:529-39
   PubMed Web of Science ®Google Scholar
• Nilvebrant L, Andersson K, et al. Tolterodine- a new bladder-selective antimuscarinic agent. Eur J Pharm 1997;327:195-207
   PubMed Web of Science ®Google Scholar
• Nilvebrant L, Hallen B, et al. Tolterodine: a new bladder selective, muscarinic receptor antagonist: pre-clinical pharmacological and clinical data. Life Sci 1997;60:1129-36
   PubMed Web of Science ®Google Scholar
• Chapple C, Nilvebrandt L. Tolterodine: selectivity for the urinary bladder over the eyes (measured by accommodation) in healthy volunteers. Drugs R D 2002;3:75-81
   PubMedGoogle Scholar
• Stahl M, Ekstrom B, et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995;14:647-55
   PubMed Web of Science ®Google Scholar
• Basra R, Wagg A, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008;102:774-9
   PubMed Web of Science ®Google Scholar
• Novara G, Galfano A, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-63
   PubMed Web of Science ®Google Scholar
• Freeman R, Hill S, et al. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003;102:605-11
   PubMed Web of Science ®Google Scholar
• Khullar V, Hill S, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004;64:269-75
   PubMed Web of Science ®Google Scholar
• Rackley R, Weiss J, et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731-6
   PubMed Web of Science ®Google Scholar
• Rogers R, Bachmann G, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J 2008;19:1551-7
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Abrams P, et al. Efficacy and tolerability of tolterodine extended-release in male and female patients with overactive bladder. Eur Urol 2007;51:1054-64
   PubMed Web of Science ®Google Scholar
• Blake-James B, Rashidian A, et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2007;99:85-96
   PubMedGoogle Scholar
• Abrams P, Kaplan S, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175:999-1004
   PubMed Web of Science ®Google Scholar
• Lee J, Kim H, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004;94:817-20
   PubMed Web of Science ®Google Scholar
• Kaplan S, Roehrborn C, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28
   PubMed Web of Science ®Google Scholar
• Kaplan S, Roehrborn C, et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the international prostate symptom score. BJU Int 2008;102:1133-9
   PubMed Web of Science ®Google Scholar
• Kaplan S, Walmsley K, et al. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2008;179(Suppl 5):S82-5
   Google Scholar
• Chapple C, Herschorn S, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2008. In press
   Google Scholar
• Rovner E, Kreder K, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008;180:1034-41
   PubMed Web of Science ®Google Scholar
• Roehrborn C, Kaplan S, et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effect of prostate size. Eur Urol 2008. In press
   Google Scholar
• Roehrborn C, Kaplan S, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS including OAB. Urology 2008;72:1061-7
   PubMedGoogle Scholar
• Gopal M, Haynes K, et al. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008;112:1311-18
   PubMed Web of Science ®Google Scholar
• Chapple C, Khullar V, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Diokno A, Appell R, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95
   PubMed Web of Science ®Google Scholar
• Callahan M. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol 2002;35:S58-67
   PubMed Web of Science ®Google Scholar
• Bharucha A, Seide B, et al. Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects. Neurogastroenterol Motil 2008;20:643-8
   PubMed Web of Science ®Google Scholar
• Choppin A, Eglen R. Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br J Pharmacol 2001;132:835-42
   PubMed Web of Science ®Google Scholar
• Malhotra B, Glue P, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007;81:377-85
   PubMed Web of Science ®Google Scholar
• Torodova A, Vonderheid-Guth B, et al. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-44
   PubMedGoogle Scholar
• Jewart R, Green J, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry 2005;13(4):324-8
   PubMed Web of Science ®Google Scholar
• Salvatore S, Serati M, et al. Cognitive dysfunction with tolterodine use. Am J Obstet Gynecol 2007;197:e8
   PubMed Web of Science ®Google Scholar
• Chu F, Dmochowski R, et al. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol 2005;192:1849-54
   PubMed Web of Science ®Google Scholar
• Anderson R, MacDiarmid S, et al. Effectiveness and tolerability of extended-release oxybutynin vs. extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:502-11
   PubMed Web of Science ®Google Scholar
• Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002;18:177-84
   PubMed Web of Science ®Google Scholar
• Chapple C, Martinez-Garcia R, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70
   PubMed Web of Science ®Google Scholar
• Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 2004;29:715-20
   Web of Science ®Google Scholar
• Simon H, Malhotra B. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Swiss Med Wkly 2009;139:146-51
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
   PubMed Web of Science ®Google Scholar
• Siami P, Seidman L, et al. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002;24:616-28
   PubMed Web of Science ®Google Scholar
• Zinner N, Mattiasson A, et al. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799-807
   PubMed Web of Science ®Google Scholar
• Roberts R, Bavendam T, et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract 2006;60:752-8
   PubMed Web of Science ®Google Scholar
• Herschorn S, Heesakkers J, et al. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 2008;24:3513-21
   PubMed Web of Science ®Google Scholar
• Rovner E, Rackley R, et al. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology 2008;72:488-93
   PubMed Web of Science ®Google Scholar
• Rogers R, Omotosho T, et al. Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. Int Urogynecol J 2009;20:381-5
   Web of Science ®Google Scholar